Nutraceuticals Research Group, School of Biomedical Sciences and Pharmacy, University of Newcastle, Hunter Medical Research Institute, New Lambton Heights, NSW 2305, Australia.
Hunter Haematology Research Group, Calvary Mater Newcastle, Waratah, NSW 2298, Australia.
J Nutr Biochem. 2014 Oct;25(10):997-1002. doi: 10.1016/j.jnutbio.2014.05.001. Epub 2014 Jun 2.
LCn-3PUFA comprised of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) offer cardioprotection involving a decrease in coagulant activity; however, the evidence is equivocal. We have previously demonstrated that the acute (24 h) effects and chronic (4 weeks) effects of LCn-3PUFA supplementation on platelet aggregation in human subjects are sex specific. This study investigated the mechanisms of the sex-dependent effects of LCn-3PUFA with 4 weeks supplementation of EPA-rich vs. DHA-rich oils on procoagulant and platelet activity in healthy subjects.
A double-blinded, placebo-controlled randomised trial was conducted in 94 healthy adults: male (n=41) and female (n=53). Platelet coagulation parameters including factors I, II, V, VII, VIII, IX, X, vWF:Ag and endogenous thrombin potential were measured at baseline and 4 weeks postsupplementation with EPA-rich or DHA-rich oil capsules.
We have previously reported that platelet aggregation is specifically reduced by supplementation with EPA in males and DHA in females. This sex-specific effect was also observed for decreases in plasma levels of Factor II (-7.9 ± 3.8%, P=.026), Factor V (-6.5 ± 4.5%, P=.022) and vWF:Ag (-7.3 ± 2.1%, P=.034) and was most pronounced in males supplemented with EPA. In contrast, DHA-mediated reduction in platelet aggregation in females was not accompanied by any significant changes in the coagulation parameters tested.
Significant interactions between sex and specific LCn-3PUFA exist to reduce procoagulant activity differentially in males vs. females and could have profound effects on managing risk of thrombotic disease.
LCn-3PUFA 由二十碳五烯酸 (EPA) 和二十二碳六烯酸 (DHA) 组成，可通过降低凝血活性提供心脏保护；然而，证据尚不一致。我们之前已经证明，LCn-3PUFA 补充剂对人类血小板聚集的急性（24 小时）和慢性（4 周）作用具有性别特异性。本研究旨在探讨 LCn-3PUFA 补充剂对健康受试者促凝和血小板活性的性别依赖性影响的机制，分别用富含 EPA 和富含 DHA 的油进行 4 周补充。
对 94 名健康成年人进行了一项双盲、安慰剂对照的随机试验：男性（n=41）和女性（n=53）。在基线和 EPA 或 DHA 补充 4 周后，测量血小板凝血参数，包括因子 I、II、V、VII、VIII、IX、X、vWF:Ag 和内源性凝血酶潜力。
我们之前报道过，EPA 补充可特异性降低男性血小板聚集，而 DHA 补充可特异性降低女性血小板聚集。这种性别特异性效应也观察到因子 II（-7.9±3.8%，P=.026）、因子 V（-6.5±4.5%，P=.022）和 vWF:Ag（-7.3±2.1%，P=.034）血浆水平的降低，在补充 EPA 的男性中最为明显。相比之下，DHA 介导的女性血小板聚集降低并不伴随任何测试凝血参数的显著变化。
LCn-3PUFA 之间存在显著的性别相互作用，可不同程度地降低男性和女性的促凝活性，对管理血栓性疾病风险可能有深远影响。
